Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha.

Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha. Abstract Text:

Michel J Perron,Matthew Stremlau,Joseph Sodroski,

Human TRIM5alpha (TRIM5alpha(hu)) potently restricts N-tropic (N-MLV), but not B-tropic, murine leukemia virus in a manner dependent upon residue 110 of the viral capsid. Rhesus monkey TRIM5alpha (TRIM5alpha(rh)) inhibits N-MLV only weakly. The study of human-monkey TRIM5alpha chimerae revealed that both the v1 and v3 variable regions of the B30.2/SPRY domain contain potency determinants for N-MLV restriction. These variable regions are predicted to be surface-exposed elements on one face of the B30.2 domain. Acidic residues in v3 complement basic residue 110 of the N-MLV capsid. The results support recognition of the retroviral capsid by the TRIM5alpha B30.2 domain.

Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha. Publishing Authors By Initials

MJ Perron,M Stremlau,J Sodroski,

For similar virus diseases: rna virus infections: retroviridae infections research abstracts see: virus diseases: rna virus infections: retroviridae infections research

PUBMED ID PMID:

MEDLINE DATE:

Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Journal of virology

VOLUME: 80

Page Numbers: 5631-6

Journal Abbreviation: J. Virol.

ISSN: 0022-538X

DAY: 3

MONTH: Jun

YEAR: 2006

Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 113724

Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha. Keywords Mesh Terms:

KEYWORDS: Retroviridae Infections

MESH TERMS: prevention & control

Chemical & Substance for Abstract: Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha. Information

Substance Name: TRIM5(alpha) protein, rhesus monkey

Registry Number: 0

Grant and Affiliation Information for Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha.

AFFILIATION: Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, 44 Binney Street, JFB 824, Boston, MA 02115, USA.

Country: United States

AGENCY: United States NIAID

GRANT: AI 60354

ACRONYM: AI

MEDLINETA: J Virol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Two surface-exposed elements of the B302/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha Related Publications

• A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.
• A human TRIM5alpha B30.2/SPRY domain mutant gains the ability to restrict and prematurely uncoat B-tropic murine leukemia virus.
• Adaptation of the human immunodeficiency virus type 1 envelope glycoproteins to new world monkey receptors.
• Antibody binding in proximity to the receptor/glycoprotein complex leads to a basal level of virus neutralization.
• Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization.
• CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
• Comparative requirements for the restriction of retrovirus infection by TRIM5alpha and TRIMCyp.
• Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.
• Functional interplay between the B-box 2 and the B30.2(SPRY) domains of TRIM5alpha.
• Inhibition of human immunodeficiency virus envelope glycoprotein- mediated single cell lysis by low-molecular-weight antagonists of viral entry.
• Modulation of retroviral restriction and proteasome inhibitor-resistant turnover by changes in the TRIM5alpha B-box 2 domain.
• The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid.
• Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5alpha.
• Unique features of TRIM5alpha among closely related human TRIM family members.